Status:
COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime
Lead Sponsor:
University of California, San Francisco
Conditions:
Focus Groups
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
In the proposed study, we plan to use a genotype to phenotype strategy to study the role of the organic anion transporter, OAT3, in drug response. More specifically we will examine the contribution of...
Detailed Description
Traditionally, clinical pharmacogenetic studies have begun with identifying a known phenotype (e.g., an aberrant response to a drug) followed by isolating the variant protein and gene responsible for ...
Eligibility Criteria
Inclusion
- Previous participation in the "SOPHIE" study;
- Has a specific genotype for OAT3
Exclusion
- Under 18 years old or over 45 years old;
- Pregnant (pregnancy status in female subjects will be determined by a urine pregnancy test before study drug administration);
- They report a prior history of any allergic reaction to cephalosporin antibiotic, or severe hypersensitivity to penicillin;
- Has a prior history of renal or hepatic dysfunction (renal and hepatic function will also be determined for each subject with prescreening blood tests);
- Taking a medication that could confound study results (such as known substrates or inhibitors of OATs);
- They do not consent to participate in the study.
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00187655
Start Date
January 1 2004
End Date
December 1 2013
Last Update
October 29 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.